title: Combined effects of quercetin and atenolol in reducing isoproterenol-induced cardiotoxicity in rats: possible mediation through scavenging free radicals.
abstract: In this investigation, combined effects of quercetin and atenolol in the regulation of isoproterenol (ISO)-induced cardiotoxicity have been evaluated in rats. While ISO administration increased the levels of serum creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH) and glutamate pyruvate transaminase (SGPT) as well as cardiac malondialdehyde (MDA); it reduced the activities of superoxide dismutase, catalase, glutathione peroxidase and the level of reduced glutathione. ISO-induced rats also exhibited ST-segment elevation and tachycardia. Oral administration of atenolol (6 mg/kg) and quercetin (5 mg/kg), along with ISO (5 mg/kg, subcutaneously) every day for 10 days markedly reduced the serum CK-MB, LDH and SGPT levels. Concomitantly the test drugs improved the status of antioxidative enzymes, decreased the cardiac MDA and nearly normalized the electrocardiogram. Electron paramagnetic resonance study also revealed a decrease in 5,5'-dimethyl-1-pyroline-N-oxide-hydroxyl radicals signal intensity when atenolol and quercetin were administered together to ISO-treated rats. In conclusion, the combined treatment of atenolol and quercetin appears to produce a better cardioprotective effect in ISO-induced animals as compared to their individual treatments, and possibly the beneficial actions are associated with the free radical scavenging action of quercetin.
authors.affiliation: School of Life Sciences, Devi Ahilya University, Takshashila Campus, Khandwa Road, Indore 452001, MP, India. sppsunanda9@gmail.com
authors.forename: Sunanda
authors.initials: S
authors.lastname: Panda
authors.forename: Anand
authors.initials: A
authors.lastname: Kar
authors.forename: Tushar
authors.initials: T
authors.lastname: Banerjee
authors.forename: Neha
authors.initials: N
authors.lastname: Sharma
mesh_terms: D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000633:toxicity*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001262:Atenolol / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004798:Enzymes / Q000378:metabolism; D016166:Free Radical Scavengers / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D007279:Injections, Subcutaneous; D007545:Isoproterenol / Q000633:toxicity*; D009206:Myocardium / Q000201:enzymology / Q000473:pathology; D009336:Necrosis; D011794:Quercetin / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000318:Adrenergic beta-Agonists; D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D004798:Enzymes; D016166:Free Radical Scavengers; D001262:Atenolol; D011794:Quercetin; D007545:Isoproterenol